Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 in relapsing/refractory autoimmune diseases
NCT07236762Phase 1Recruiting
- Sponsor
- China Immunotech
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of YTS-109 in systemic lupus erythematosus (SLE), lupus nephritis (LN), immune thrombocytopenia (ITP) and 5 more, sponsored by China Immunotech. Primary endpoints: Adverse Events at 52 weeks and Efficacy Assessment at 52 weeks. Started Nov 2025; status: recruiting.
02
Drugs
YTS-109
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)immune thrombocytopenia (ITP)Sjogren's syndromesystemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07236762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236762.